🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia

Recruitingn/aAges 18 Years - anyAllOslo University Hospital
NCT06468774 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Above 18 years and has given informed written consent for treatment and study participation For the patient groups : Group 1: Has CTA or ultrasound diagnosed MALS and is scheduled operative treatment. Group 2: Has CTA or ultrasound diagnosed CMI and is scheduled operative or endovascular treatment. For the control group: Group 3- Has ultrasound based diagnosis of cholelithiasis and is scheduled for cholecystectomy. Group 4- Has established Mb Crohn diagnosis and under gastric lab follow-up. Group 5- Young healthy blood donors of mean age 45 years and has excluded MALS or CMi with ultrasound. Group 6- Healthy blood donors of mean age 70 years and has excluded MALS or CMi with ultrasound. Exclusion Criteria: Age less than 18 years Has nor given written consent. \-
💊

What it tests

  • Laparoscopic surgery
📍

Where

1 site
Department of vascular surgery, Oslo University Hospital
Oslo, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy